Paper Details

  1. Home
  2. Paper Details

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Author: BorlandJulie, CastellinoStephen, ChenShuguang, GutaPhyllis, HoskingLouise, LouYu, MostellerMichael, PeppercornAmanda, PiscitelliStephen C, RubioJustin P, SavinaPaul, SongIvy, WagnerDavid, WajimaToshihiro, WilfretDavid

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolutegravir (DTG) should be administered at a higher dose (50 mg twice daily) when co-administered with efavirenz (EFV) or tipranavir/ritonavir (TPV/r) due to the significant reduction in DTG exposure. Alternative regimens without inducers should be considered for integrase inhibitor-resistant patients.
Paper Details　
Original Abstract of the Article :
PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158172/

データ提供：米国国立医学図書館（NLM）

Dolutegravir: A New Antiretroviral Facing the Shifting Sands of Drug Interactions

Dolutegravir (DTG), a promising new antiretroviral drug for the treatment of HIV infection, has shown considerable effectiveness. However, like a camel navigating the vast desert of drug interactions, DTG's efficacy can be influenced by other medications. This research investigates the impact of two enzyme inducers, efavirenz (EFV) and tipranavir/ritonavir (TPV/r), on the pharmacokinetics of DTG. The study revealed that both EFV and TPV/r significantly reduced DTG exposure, indicating that dose adjustments may be necessary when these drugs are co-administered.

Navigating the Desert of Drug Interactions: Finding the Right Dosage

The study found that co-administration of DTG with EFV or TPV/r resulted in a significant decrease in DTG's bioavailability. This finding highlights the importance of careful consideration of drug interactions when prescribing DTG. The researchers recommend an increased dose of DTG when co-administered with EFV or TPV/r to maintain therapeutic efficacy. Alternatively, alternative regimens that avoid enzyme inducers should be considered in patients with integrase inhibitor-resistant HIV.

A Balanced Approach to HIV Treatment: Understanding the Landscape

The study's findings underscore the need for a nuanced approach to HIV treatment, taking into account the complex interplay of drug interactions. By carefully considering the potential impact of other medications on DTG's efficacy, healthcare professionals can optimize treatment strategies for patients living with HIV. This research provides valuable insights into the desert landscape of drug interactions, helping to guide clinicians in ensuring optimal treatment outcomes for their patients.

Dr.Camel's Conclusion

This research provides a valuable roadmap for navigating the challenging terrain of drug interactions when treating HIV. Like a skilled navigator, we must consider the potential impact of other medications on DTG's efficacy to ensure optimal treatment outcomes. This study highlights the importance of a nuanced approach to HIV treatment, recognizing the intricate interactions between different drugs and the potential need for dose adjustments to achieve a balanced therapeutic effect.

Date :
  1. Date Completed 2015-05-25
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25146692

DOI: Digital Object Identifier

PMC4158172

Related Literature

Article Analysis
・Effects of dolutegravir・Effects of tipranavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.